InnoCan Pharma Corporation (INNPF) Comparison with companies in other sectors?

InnoCan Pharma Corporation has a share price of 292.42M. You can analyze InnoCan Pharma Corporation (INNPF) competitors across different market sectors through stock heatmaps.

What are INNPF's NET and operating margins?

InnoCan Pharma Corporation (INNPF) operating margin is around 0.01, and net profit margin is approximately -0.02 as of the latest reports.

In what way does INNPF's earnings per share (EPS) trend reflect its financial momentum?

InnoCan Pharma Corporation (INNPF) EPS is -0.01 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for InnoCan Pharma Corporation is -16.44, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for InnoCan Pharma Corporation?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for InnoCan Pharma Corporation like P/E which is -73.53, P/B which is 10.20, and PEG which is -1.09. Compare them with sector averages to evaluate if the stock is priced fairly.

InnoCan Pharma Corporation

INNPF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$0.16

$0.00(0.00%)

InnoCan Pharma Corporation (INNPF) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.01

P/E Ratio

-16.44

ROE

-0.13%

Net Margin

-0.02%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$48.06M

Shares OutstandingTotal number of shares issued

$292.42M

Book Value/ShareNet worth per share

$0.02

Revenue/ShareAnnual revenue per share

$0.10

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.01

Net MarginNet income as percentage of revenue

-2.13%

Operating MarginOperating income as percentage of revenue

1.49%

ROEReturn on shareholders' equity

-13.10%

ROAReturn on total assets

-6.00%

ROCEReturn on capital employed

5.54%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.00

Cash/ShareCash and equivalents per share

$0.02

FCF YieldFree cash flow as percentage of market cap

-1.00%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for INNPFFinancial Ratios Analysis details for INNPF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for INNPFSector Benchmarking details for INNPF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for InnoCan Pharma Corporation Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of InnoCan Pharma Corporation. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account InnoCan Pharma Corporation's unique business strengths and challenges.

Key Financial Metrics for InnoCan Pharma Corporation

For InnoCan Pharma Corporation, essential financial indicators include EPS -0.01, PE -16.44, and ROE -0.13. These key ratios reveal insights into InnoCan Pharma Corporation's profitability, valuation, and operational health. Understanding these metrics enables you to compare InnoCan Pharma Corporation with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of InnoCan Pharma Corporation

Metrics like Net Margin -2.13% and ROA -6.00% shed light on how well InnoCan Pharma Corporation is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether InnoCan Pharma Corporation can sustain its operations and continue growing in the future.

Valuation and Market Position of InnoCan Pharma Corporation

Using ratios such as P/B Ratio 10.20 and PEG Ratio -1.09, investors can assess whether InnoCan Pharma Corporation is appropriately valued based on its financials and growth potential. These figures, combined with InnoCan Pharma Corporation's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for InnoCan Pharma Corporation

Financial health indicators, such as Debt/Equity Ratio 0.28 and Cash Flow $-0.00, provide a snapshot of InnoCan Pharma Corporation's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like InnoCan Pharma Corporation, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for InnoCan Pharma Corporation

Investing in InnoCan Pharma Corporation based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at InnoCan Pharma Corporation focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;